CeriBell (NASDAQ:CBLL) CTO Sells $47,535.58 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,979 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $24.02, for a total value of $47,535.58. Following the completion of the sale, the chief technology officer owned 194,729 shares in the company, valued at approximately $4,677,390.58. The trade was a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Up 0.0%

NASDAQ:CBLL traded up $0.01 during midday trading on Tuesday, reaching $23.95. The company had a trading volume of 243,381 shares, compared to its average volume of 457,237. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The firm has a market capitalization of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The stock’s fifty day simple moving average is $19.77 and its 200-day simple moving average is $19.27.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on CBLL shares. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. BTIG Research boosted their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of CeriBell during the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd raised its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the third quarter worth approximately $33,000. CWM LLC lifted its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.